Moderna Inc. (NASDAQ: MRNA) is a biotechnology company that develops innovative vaccines based on mRNA technology. Before the Coronavirus Pandemic, the company was making waves with promising cancer vaccines and regenerative therapeutics. More recently, the company developed the second COVID-19 vaccine to be approved by the FDA.
The company advised this week that it is ahead of schedule with 200 million vaccine doses that will be delivered to the U.S. federal government. It will deliver two shipments of 100 million doses in March and July, months ahead of the expected delivery dates. Moderna is expected to generate at least $10 billion in revenue from vaccines over the next year. The company’s previous high revenue figure was $205.83 million in 2017. There’s no overstating how important the Coronavirus vaccine is for the company’s growth.
Earnings are expected to increase by 18.9% in the current fiscal year, although the figure could be revised much higher if the company can increase its vaccine production output. With a high-end target price of $206.00, there’s plenty of potential upside for investors who buy shares in February.
- 1 Year Price Growth: 25%
- YTD Price Growth: 20%
- 3 Month Price Growth: 85%
All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.